3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement
7 January 2013
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex® Scaffold 3D cell culture technology
Sedgefield, UK. 07th January 2013 – Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has entered into a co-marketing agreement with the pre-clinical Oncology CRO Oncotest GmbH.
Under the terms of the partnership, Oncotest will offer its clients automated assays based on Alvetex Scaffold technology, complementing their well known 3D Tumour Clonogenic Assay technology.
Prof. Stefan Przyborski, founder and CSO of Reinnervate described the benefits of the 96 well plates for cancer cell cytotoxicity testing; “The Alvetex Scaffold 96 well plate allows scientists to grow tumour cells in 3D, better mimicking the way these cells grow in vivo. It is very easy to start using 3D cell culture with Alvetex technology. You simply seed the cells, add your existing media and place in your standard incubator. There is no struggling with new and sometimes cumbersome protocols required with other 3D technologies such as collagen gels or hanging drops.” He then went on to say, “We have shown that the Alvetex Scaffold 96 well plates work seamlessly with automated platforms and standard cell health assays such as MTT, XTT, Cell Titer-Glo® and many others.”
Prof. Heiner Fiebig, founder and CEO of Oncotest said, “We are very pleased to be able to offer cancer cell cytotoxicity assays using Alvetex Scaffold 96 well plates to our clients. We have looked at several different technologies and found Alvetex Scaffold to be the simplest and most reliable solution. We particularly value the ease of use, ability to automate the entire workflow and the ability to isolate protein and RNA from the treated cells to study drug effects post-treatment. The combination of Alvetex Scaffold, state-of-the-art co-culture techniques and our automated 96 well 3D assay technology will also potentially allow the study of effects of anti-cancer molecules which target parts of the tumour microenvironment. This powerful ex vivo culture system will be a very exciting new tool for our clients. The assay platform can be used with both Oncotest’s patient-derived tumour xenografts (as an ex vivo assay) and for established tumour cell lines (as an in vitro assay).”
Oncotest will begin offering services immediately to existing clients, and will offer a new introductory screening service for companies new to 3D cell culture who want to try out 3D culture based oncology services.
Note:Reinnervate Ltd (County Durham, England) was acquired by REPROCELL Inc (Yokohama, Japan) in August 2014. Biopta Ltd (Glasgow, Scotland) was acquired by REPROCELL in November 2015. REPROCELL Europe Ltd was established by merging Reinnervate and Biopta in June 2016.